Compare Cipla with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ORCHID PHARMA LTD - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ORCHID PHARMA LTD CIPLA/
ORCHID PHARMA LTD
 
P/E (TTM) x 23.6 -0.5 - View Chart
P/BV x 2.4 0.1 2,046.9% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 CIPLA   ORCHID PHARMA LTD
EQUITY SHARE DATA
    CIPLA
Mar-19
ORCHID PHARMA LTD
Sep-13
CIPLA/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs678194 349.5%   
Low Rs48435 1,382.3%   
Sales per share (Unadj.) Rs198.2276.5 71.7%  
Earnings per share (Unadj.) Rs18.5-79.2 -23.4%  
Cash flow per share (Unadj.) Rs35.0-43.5 -80.5%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs186.353.9 345.4%  
Shares outstanding (eoy) m805.7070.45 1,143.6%   
Bonus/Rights/Conversions ESOPESOP-  
Price / Sales ratio x2.90.4 707.6%   
Avg P/E ratio x31.4-1.4 -2,169.4%  
P/CF ratio (eoy) x16.6-2.6 -630.1%  
Price / Book Value ratio x3.12.1 146.9%  
Dividend payout %16.20-   
Avg Mkt Cap Rs m468,0318,067 5,802.1%   
No. of employees `00022.62.8 808.7%   
Total wages/salary Rs m28,5652,527 1,130.4%   
Avg. sales/employee Rs Th7,053.16,956.1 101.4%   
Avg. wages/employee Rs Th1,261.5902.5 139.8%   
Avg. net profit/employee Rs Th659.1-1,993.0 -33.1%   
INCOME DATA
Net Sales Rs m159,71019,477 820.0%  
Other income Rs m4,766407 1,170.4%   
Total revenues Rs m164,47519,884 827.2%   
Gross profit Rs m30,9731,103 2,809.1%  
Depreciation Rs m13,2632,519 526.5%   
Interest Rs m1,6845,227 32.2%   
Profit before tax Rs m20,791-6,236 -333.4%   
Minority Interest Rs m-17220 -871.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0511 0.0%   
Tax Rs m5,695-125 -4,549.0%   
Profit after tax Rs m14,924-5,580 -267.4%  
Gross profit margin %19.45.7 342.6%  
Effective tax rate %27.42.0 1,364.4%   
Net profit margin %9.3-28.7 -32.6%  
BALANCE SHEET DATA
Current assets Rs m124,26611,014 1,128.2%   
Current liabilities Rs m37,71532,060 117.6%   
Net working cap to sales %54.2-108.1 -50.2%  
Current ratio x3.30.3 959.1%  
Inventory Days Days9195 95.5%  
Debtors Days Days9534 282.7%  
Net fixed assets Rs m105,19029,440 357.3%   
Share capital Rs m1,611705 228.7%   
"Free" reserves Rs m148,5112,043 7,270.7%   
Net worth Rs m150,1233,800 3,950.7%   
Long term debt Rs m38,3019,018 424.7%   
Total assets Rs m239,63346,510 515.2%  
Interest coverage x13.3-0.2 -6,909.8%   
Debt to equity ratio x0.32.4 10.8%  
Sales to assets ratio x0.70.4 159.2%   
Return on assets %6.9-0.8 -911.9%  
Return on equity %9.9-146.9 -6.8%  
Return on capital %11.8-3.7 -317.0%  
Exports to sales %34.737.9 91.6%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs m55,4197,378 751.2%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m57,4107,513 764.1%   
Fx outflow Rs m19,0415,649 337.1%   
Net fx Rs m38,3681,865 2,057.8%   
CASH FLOW
From Operations Rs m16,9111,682 1,005.6%  
From Investments Rs m-16,687-9,860 169.2%  
From Financial Activity Rs m-3,4876,644 -52.5%  
Net Cashflow Rs m-3,451-1,535 224.8%  

Share Holding

Indian Promoters % 16.0 32.3 49.5%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.6 265.2%  
FIIs % 23.7 3.3 718.2%  
ADR/GDR % 1.1 4.6 23.9%  
Free float % 26.2 55.3 47.4%  
Shareholders   161,166 84,811 190.0%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  BIOCON   FULFORD INDIA  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (2QFY19); Net Profit Up 67.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended September 2018, ORCHID PHARMA LTD has posted a net profit of Rs 231 m (up 67.1% YoY). Sales on the other hand came in at Rs 1 bn (down 31.9% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Sep 19, 2019 03:35 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS